Viatris VTRS Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Developed Markets Segment | $8.68B-0.1% | $8.55B-4.6% | $8.45B-7.7% | $8.49B-8.2% | $8.69B-6.4% | |
| Emerging Markets Segment | $2.23B+3.6% | $2.22B-1.9% | $2.17B-8.9% | $2.13B-14.3% | $2.15B-15.5% | |
| Greater China | $2.46B+12.7% | $2.33B+7.6% | $2.28B+5.6% | $2.23B+3.8% | $2.18B+1.9% | |
| Japan, Australia and New Zealand Segment | $1.19B-8.8% | $1.2B-11.3% | $1.23B-11.5% | $1.27B-8.0% | $1.31B-6.6% | |
| Selling, general and administration by Business | ||||||
| Developed Markets Segment | $966.4M-7.8% | $967.9M-11.8% | $986.5M-10.7% | $1.01B-11.6% | $1.05B-6.9% | |
| Emerging Markets Segment | $306.8M+2.2% | $310M0.0% | $296.1M-9.9% | $300.6M-11.4% | $300.2M-14.3% | |
| Greater China | $514.1M+0.4% | $512.2M-1.2% | $504.2M-1.9% | $505.9M-1.0% | $512.1M-0.1% | |
| Japan, Australia and New Zealand Segment | $154.9M-6.3% | $158.9M-5.6% | $163.2M-2.3% | $165.4M-3.4% | $165.3M-5.2% | |
| Cost of Sales by Business | ||||||
| Greater China | $260.7M+6.3% | $250.6M+2.0% | $248.7M+4.9% | $248.6M+11.4% | $245.3M+13.9% | |
| Foreign currency translation by Business | ||||||
| Developed Markets Segment | $234M+685% | $547.1M+246% | $137.6M-52.6% | $333.8M+532% | $29.8M— | |
| Greater China | $12.1M— | $11.7M— | -$3.3M— | —— | —— | |
| Goodwill, Impaired, Accumulated Impairment Loss by Business | ||||||
| Developed Markets Segment | $12.76B+113% | $12.76B+243% | $10.5B+183% | $8.24B+160% | $5.98B+127% | |
| Emerging Markets Segment | $2B+220% | $2B+705% | $1.37B+454% | $998M+314% | $623M+166% | |
| Japan, Australia and New Zealand Segment | $2.61B+52.9% | $2.61B+141% | $2.31B+203% | $2.01B— | $1.7B— | |
| Goodwill by Business | ||||||
| Developed Markets Segment | $20.01B-21.8% | $19.79B-28.8% | $21.52B-23.6% | $23.66B-16.7% | $25.58B-12.0% | |
| Emerging Markets Segment | $3.19B-25.8% | $3.19B-31.8% | $3.56B-24.2% | $3.94B-18.3% | $4.3B-13.8% | |
| Greater China | $3.73B+0.7% | $3.71B+0.3% | $3.7B-0.3% | $3.7B-0.4% | $3.7B-0.9% | |
| Japan, Australia and New Zealand Segment | $0-100% | $0-100% | $295.1M-84.2% | $602.5M-72.8% | $895.5M-65.4% | |
| Net Sales by Product | ||||||
| Brands | $9.4B+4.3% | $9.18B-0.2% | $9B-4.6% | $8.93B-7.1% | $9.01B-7.0% | |
| Celebrex ® | $276.6M-0.1% | $272.9M-4.4% | $273.8M-6.7% | $274.6M-9.7% | $276.8M-11.8% | |
| Creon ® | $380.8M+13.5% | $365.8M+11.5% | $357.3M+12.2% | $348.8M+12.0% | $335.6M+9.2% | |
| Dymista ® | $158.1M-13.4% | $163.6M-13.0% | $166.3M-13.2% | $176M-8.5% | $182.6M-6.4% | |
| Effexor ® | $260.4M+3.0% | $257.7M+1.9% | $254.1M-0.9% | $253.2M-0.9% | $252.8M-1.9% | |
| EpiPen® Auto-Injectors | $474.1M+16.1% | $469.7M+19.8% | $463.8M+14.3% | $429.8M+3.7% | $408.5M-4.2% | |
| Generics | $5.12B-3.0% | $5.07B-7.8% | $5.07B-8.9% | $5.14B-8.1% | $5.27B-6.4% | |
| Lipitor | $1.62B+10.6% | $1.55B+5.5% | $1.53B+2.4% | $1.51B+0.6% | $1.47B-4.1% | |
| Lyrica ® | $495M+0.2% | $487M-1.7% | $494.2M-1.5% | $497.6M-3.1% | $493.8M-6.2% | |
| Norvasc | $747.6M+11.7% | $709.9M+5.4% | $700.9M+3.2% | $690.1M+0.7% | $669.3M-5.2% | |
| Viagra ® | $404.7M+2.9% | $408.2M+3.2% | $392.6M-1.7% | $387.6M-5.4% | $393.4M-5.1% | |
| Xalabrands | $160.5M-0.3% | $158.4M-4.8% | $153.5M-13.5% | $156.1M-15.3% | $161M-14.8% | |
| Xanax ® | $142.4M-0.3% | $139.9M-3.5% | $136.9M-4.7% | $141.3M+6.1% | $142.8M-4.5% | |
| Yupelri ® | $271.1M+12.2% | $266.9M+11.9% | $262.9M+13.1% | $253.7M+11.0% | $241.6M+5.5% | |
| Zoloft ® | $267.3M+12.4% | $254.9M+8.1% | $246.3M+2.8% | $240.1M-0.6% | $237.9M+0.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Viatris break its business down?
- Viatris (VTRS) reports net sales by business across 4 parts — Developed Markets Segment, Emerging Markets Segment, Greater China and Japan, Australia and New Zealand Segment. Each is extracted from the segment footnotes and tracked over time.
- Where does Viatris's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Viatris's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
